Alamar Biosciences, Inc.
Fremont, CA Alamar Biosciecnes, Inc.
- UEI
- WM9YMMU3P233
- CAGE
- 87PS4
- Primary NAICS
- 334516 Analytical Laboratory Instrument Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 47071 Bayside Pkwy, Fremont, CA 94538, USA
- Website
- alamarbio.com
- Founded
- 2018
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $187,070 |
| FY2025 | $1,076,366 |
| FY2024 | $3,016,260 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $187,070 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Alamar Biosciences, Inc., a for-profit biomedical research instrument and diagnostics manufacturer based in Fremont, California, sells high-multiplex proteomic analysis platforms, immunoassay panels, and laboratory testing services to the National Institutes of Health and the Department of Veterans Affairs as a prime contractor, competing on full-and-open procurements with no set-aside designations.
Alamar's federal footprint centers on a narrow but high-value customer base within NIH's intramural research divisions. The National Institute on Aging accounts for 81% of recent awards by dollar volume ($3.5 million across six purchase orders), followed by the Veterans Integrated Service Network 7 at the Atlanta VA Medical Center (one $510 thousand purchase order for military exposure research), the National Institute on Drug Abuse (three awards, $187 thousand combined), the National Institute of Mental Health (two awards, $60 thousand), and the NIH Office of Logistics and Acquisition Operations (one $57 thousand order). All thirteen awards are prime contracts, predominantly firm-fixed-price purchase orders, with zero subcontract engagement.
Alamar's capability portfolio is narrowly specialized around its proprietary NULISA and NULISASEQ platforms — ultra-high-sensitivity multiplexed proteomics systems measuring 100–220+ disease biomarkers simultaneously at femtogram/mL sensitivity levels. Representative work includes a $2.75 million ARGO HT instrument and CNS Disease Panel delivery to NIA (September 2024); a $324 thousand NULISAseq Inflammation Panel 250 reagent supply contract with NIA (April 2025); a $510 thousand high-multiplex proteomic platform for neurotrauma and inflammatory biomarker research at the Atlanta VA Medical Center supporting burn pit exposure studies (September 2025); and a $99.99 thousand NULISAseq Neuro 220 Panel order from the National Institute on Aging for ultra-high-sensitivity detection of Abeta, tau, neurofilament light, and neuroinflammatory markers (September 2026). Alamar also provides laboratory testing services, maintenance and repair support for installed systems, and bulk reagent supplies. The vendor competes on sole-source and small-business sources-sought procurements, leveraging equipment installed at customer labs and the proprietary nature of its assay platforms.
Activity has remained modest and relatively flat — four awards in 2024, five in 2025, and four in 2026 — with combined obligated value of $4.3 million. Only three awards ($165 thousand combined) face completion within the next twenty-four months, placing limited recompete pressure in the near term. Alamar holds no position on government-wide vehicles, IDIQs, BPAs, or GWACs; all work flows through direct purchase orders. Customer concentration is acute: NIA represents the vendor's dominant installed base and repeat buyer, while the VA and other NIH institutes represent opportunistic, lower-volume engagements. The vendor operates entirely as a prime with no identified subcontractor relationships, suggesting a capital-intensive, proprietary-technology business model with minimal partnering for federal work.
Quick answers
Is Alamar Biosciences, Inc. registered in SAM.gov?
Yes. Alamar Biosciences, Inc.'s SAM.gov registration is active through January 23, 2027.
How much has Alamar Biosciences, Inc. received in federal contracts?
Federal contracts obligated $1,076,366 to Alamar Biosciences, Inc. in fiscal year 2025 and $4,279,696 in fiscal years 2023 through 2027.
How does Alamar Biosciences, Inc. rank among federal contractors?
Alamar Biosciences, Inc. ranked #48 in NAICS 325413, #52 in PSC 6550 and #77 in PSC 6525 in FY2025.
What is Alamar Biosciences, Inc.'s most recent federal award?
Alamar Biosciences, Inc.'s most recent federal contract award is Nimh: service: nulisaseq inflammation panel assay service: severable (75N98026P01744), from Office of Logisitics and Acquisition Operations (NIH), on September 21, 2026.
On GovTribe
See Alamar Biosciences, Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors